Heterozygous dominant gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 (STAT1) have been described as associated with chronic mucocutaneous candidiasis (CMC), disseminated fungal infections, autoimmunity, arterial aneurysms, squamous cell carcinomas, and viral and mycobacterial infections. [1] [2] [3] [4] [5] The majority of GOF mutations reported to date are located in the DNA-binding and coiled-coil domains, with 2 reported in the SH2 domain. 1, 6 These mutations are associated mostly with excessive STAT1 phosphorylation, enhanced interferon target gene expression, and diminished IL-17-producing T-cell numbers. [3] [4] [5] IFN-g activates STAT1 through Janus tyrosine kinasemediated phosphorylation of a single tyrosine (Y701) at the C-terminus. Posttranslational modifications of STAT molecules regulate their function. Sumoylation is a posttranslational reversible modification of cellular proteins through conjugation of small ubiquitin-related modifier (SUMO), an approximately 11-kDa ubiquitin-like protein that is covalently attached through a cascade of enzymatic reactions. The conjugation of SUMO to a specific lysine residue in a protein occurs within the SUMO consensus motif CKX(E/D), where C represents a large hydrophobic residue, K is the lysine to which SUMO is attached, and X represents any amino acid. [7] [8] [9] This posttranslational modification affects a variety of biological processes, such as regulation of transcription, intracellular trafficking, signal transduction, transcription regulators (IkBa), and others. [8] [9] [10] [11] On STAT1, SUMO conjugation occurs at a single lysine at 703 within the consensus motif 702 IKTE 705 at the C-terminal region. Previous studies have demonstrated that targeted mutations in this motif of STAT1 lead to enhanced response to IFN-g and enhanced phosphorylation. [12] [13] [14] [15] We identified a novel STAT1 GOF mutation in the tail segment domain E705V in a patient with disseminated Rhodococcus equi infection, Norwegian scabies, CMC, and fatal squamous cell carcinoma. This mutation is adjacent to leucine 706, where the wellcharacterized dominant negative loss-of-function (LOF) STAT1 mutation L706S is associated with disseminated mycobacterial disease. 1, 16 The E705V mutant leads to decreased sumoylation of STAT1, excessive STAT1 phosphorylation, atypical nuclear paracrystal accumulation, and enhanced IFN-g target gene expression. This mutation disrupts a posttranslational modification of STAT1, indicating a potential molecular mechanism for GOF STAT1 mutations.
METHODS

Cell lines and blood samples
COS-7 cells (ATCC, Manassas, Vas) and the human fibrosarcoma STAT1-deficient cell line U3C (kindly donated by Dr J. L. Casanova, Rockefeller University, New York, NY) were maintained in culture in a humidified 5% CO 2 incubator in Dulbecco modified Eagle medium and RPMI (Gibco Laboratories, Carlsbad, Calif), respectively, supplemented with 10% FCS, 2 mmol/L L-glutamine, and antibiotics. Transient transfections were performed with Lipofectamine 2000 Transfection Reagent (Life Technologies, Grand Island, NY), according to the manufacturer's recommendations. In addition, PBMCs from patients and healthy donors were used for in vitro assays. Samples were collected under institutional review board-approved protocols. The patient provided written informed consent, and healthy volunteer blood samples were obtained through the Department of Transfusion Medicine, National Institutes of Health. Healthy control subjects were age and sex matched.
STAT1 sequencing
Primers spanning exons and flanking splice sites of human STAT1 and full-length cDNA were designed by using Primer Select (Lasergene; DNASTAR, Madison, Wis). Genomic DNA and total RNA were extracted from primary blood cells, and genomic amplification was performed with Platinum PCR Supermix High Fidelity (Invitrogen, Carlsbad, Calif). Sequencing was done with Big Dye Terminators v3.1 (Applied Biosystems, Foster City, Calif) run on an Applied Biosystems 3730XL sequencer and aligned to the consensus sequence NM_007315.3 by using Sequencer software (Gene Codes, Ann Arbor, Mich).
Constructs
Mutated STAT1 sequences and green fluorescent protein (GFP)-tagged constructs were created (BioInnovatise, Rockville, Md) by using a STAT1 expression vector (Origene Technologies, Rockville, Md). pSG5-His-SUMO1 and Flag-sentrin-specific protease (SENP) 1 constructs were obtained from Addgene (Cambridge, Mass). 17, 18 All plasmids were isolated with the QIAprep kit (Qiagen, Hilden, Germany), according to the manufacturer's recommendations, and mutations were verified by means of sequencing.
Evaluation of STAT1 activation
Tyrosine (Tyr701, Y701) STAT1 phosphorylation (pSTAT1) was assayed in transfected cells (wild-type [WT], STAT1 mutants, and SENP-1 constructs) stimulated with IFN-g (1000 IU/mL). IFN-g was added to the cell-culture medium for 30 minutes before addition of the kinase inhibitor staurosporine (0.5 mmol/L; Calbiochem, Gibbstown, NJ) or the phosphatase inhibitor pervanadate, 15 and incubation continued for 30 minutes. Cells were then lysed in lysis buffer (Cell Signaling Technology, Danvers, Mass) containing protease and phosphatase inhibitors (Calbiochem) and analyzed by using immunoblotting. Determination of DNA-binding activity and transcriptional activity was assayed through an ELISA-like colorimetric assay (TRANSAM; Active Motif, Carlsbad, Calif) and a dual luciferase assay (Promega, Madison, Wis), respectively, as previously described. 4, 5 Evaluation of gene expression and cytokine production U3C-transfected cells and frozen stored PBMCs from the patients and healthy donors were used. Gene expression was assayed in cells left unstimulated or stimulated with IFN-g (1000 IU/mL) for 6 hours by using quantitative RT-PCR with TaqMan expression assays (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a normalization control. Evaluation of cytokine release was performed in cells stimulated with IFN-g plus LPS (200 ng/mL) for 24 hours. Culture supernatants were assayed further by using a custom bead-based cytokine assay (Bio-Plex; Bio-Rad Laboratories, Hercules, Calif).
Immunoprecipitation and immunoblotting
COS-7 and U3C or U3A cells were transiently transfected with WT or mutant STAT1 constructs and SUMO1 construct. Cells were lysed in lysis buffer supplemented with N-ethylmaleimide (20 mmol/L; Sigma, St Louis, Mo) and protease inhibitors. For immunoprecipitation, whole-cell lysates were incubated with anti-STAT1 antibody (or isotype control antibody; Santa Cruz Biotechnology, Dallas, Tex) and protein G-Sepharose (Amersham Biosciences, Piscataway, NJ) overnight at 48C. Beads were washed and heated, and proteins were resolved by means of immunoblotting for SUMO-STAT1 proteins. For analysis of cell lysates, equal amounts of protein were transferred to polyvinylidene difluoride membranes and incubated with the primary antibodies anti-pSTAT1 Tyr701, anti-STAT1, anti-SENP1 (Cell Signaling), and anti-SUMO-1 (Abcam, Cambridge, United Kingdom). Blots were stripped and reprobed with anti-STAT1 and anti-tubulin (Millipore, Temecula, Calif) antibodies to assess protein loading.
Evaluation of T H 17 response
Frozen PBMCs obtained from the patient and 2 healthy donors were thawed when cells (10 6 ) were either unstimulated or stimulated with phorbol 12-myristate 13-acetate (20 ng/mL; Sigma) and ionomycin (1 mmol/L; Sigma) in the presence of brefeldin A (10 mg/mL; Sigma) at 378C overnight. For detection of intracellular cytokines, cells were stained with Live/Dead Fixable Yellow Dead Cell Stain Kit (Invitrogen), as well as for extracellular CD3 (eVolve605), CD8-allophycocyanin-eFluor780 (eBioscience, San Diego, Calif), CD45RO-phycoerythrin (PE)-CF594 (BD Biosciences, San Jose, Calif), and CD27-BV421 (BioLegend, San Diego, Calif) for 30 minutes. Cells were fixed (paraformaldehyde 4%), permeabilized, and stained for intracellular antigens with CD4-PE-Cy7 (BD Biosciences), IL-17A PE, IFN-g fluorescein isothiocyanate, and TNF-a-allophycocyanin (eBioscience). Data were collected with an LSR Fortessa (BD Biosciences) and analyzed with FlowJo software (TreeStar, Ashland, Ore) by gating on lymphocytes (forward and side scatter) and viable
Confocal microscopy
Transfected U3C cells carrying WT-STAT1-GFP or the E705V-STAT1-GFP were fixed and assayed, as previously described. 15 Confocal microscopy on fixed cells was performed on a Leica SP5 microscope (Leica Microsystems, Mannheim, Germany) by using a 63X/1.4NA oil immersion objective and hybrid HyD detectors. Fluorochromes were excited by using diode 405-nm and argon 488-nm lasers.
Molecular modeling and molecular dynamics
A homology model of the complete WT-STAT1 protein was produced by using the I-TASSER server 19, 20 because existing crystal structures of STAT1 (PDB codes 1YVL and 1BF5) have missing residues. Initial models of the mutant proteins were generated in the program Chimera. 21 Molecular dynamics (MD) simulations were performed on the nonphosphorylated WT structure and each of the mutant models with the CHARMM27 22 force field under isobaric-isothermal conditions with periodic boundary conditions by using the NAMD 23 program (version 2.7) on the Biowulf Linux cluster (National Institutes of Health, Bethesda, Md). Each model was explicitly solvated with TIP3P water molecules and Na 1 and Cl 2 neutralizing counterions by using the VMD program. 24 Electrostatic interactions were calculated with the Particle-Mesh Ewald summation. Before the start of the simulation, energy minimization was performed, followed by slow warming to 310 K in 10 K increments of 5 ps each. Production runs were conducted at 310 K for 150 ns. For all simulations, a 2-fs integration time step was used along with a 12-A nonbonded term cutoff. Langevin dynamics were used to maintain temperature, and a modified Nos e-Hoover Langevin piston was used to control pressure. The average solvent-accessible surface area for Tyr701 in each of the MD trajectories was calculated by using VMD.
Statistical analysis
Results are means 6 SDs. Differences between groups were assessed by using the Student t test with GraphPad Prism software (GraphPad Software, San Diego, Calif). Statistical significance was set as a P value of less than .05.
RESULTS
Patient's clinical description
At age 34 years, a white man presented with subacute fever and respiratory symptoms. Bilateral cavitary lung lesions were seen on a chest computed tomographic scan (Fig 1, A) , and Rhodococcus equi was recovered from his blood and bronchoalveolar lavage fluid. He was successfully treated with a combination of vancomycin and ciprofloxacin. He had a history of recurrent sinopulmonary infections since childhood, as well as hypothyroidism, hypogonadism, and CMC. His CMC was with an azole-resistant Candida albicans and involved the oral mucosa, esophagus, toenails, and fingernails (Fig 1, B) . Because of refractory esophageal candidiasis, he had esophageal strictures and dysphagia, which required repeated esophageal dilations. Dermatotomal zoster recurred during adolescence. Severe Norwegian scabies involving his extremities, face, and torso was successfully treated with ivermectin and topical permethrin. The patient was T lymphopenic with hypergammaglobulinemia as follows: CD3
1 , 348/mL (reference value, 615-2348/mL); CD4 1 , 176/mL (334-1556/mL); CD8 , 36/mL (109-607/mL). Serum immunoglobulin levels were as follows: IgG, 1986 mg/dL (700-1600 mg/dL); IgA, 29 mg/dL (70-400 mg/dL); IgM, 214 mg/dL (40-230 mg/dL); and IgE, 22.9 mg/dL (0-90 mg/ dL). Positive anti-nuclear antibodies (6.4 EU [normal range, 0-0.9 EU)] were detected, whereas others were negative, including anti-extractable nuclear antigens, anti-thyroglobulin antibody, thyroid peroxidase antibody, thyrotropin receptor antibody, anti-parietal antibody, intrinsic factor antibody, antiliver-kidney-microsomal antibody, tissue transglutaminase IgA antibody, GAD65 antibody, anti-mitochondrial antibody, and anti-smooth muscle antibody.
At age 36 years, he was given a diagnosis of stage IIIA squamous carcinoma of the esophagus, for which he underwent chemotherapy. R equi pneumonia recurred at age 36 years, as did CMC. The patient died of further complications of his squamous carcinoma, and no further material is available for testing. His father had hypothyroidism, diabetes, CMC, and recurrent pulmonary infections and died from Pseudomonas pneumonia. His mother and sister were healthy.
STAT1 mutation
The patient's severe pulmonary infections and CMC led to genetic investigation of STAT1. Sequencing of STAT1 genomic DNA and cDNA identified the novel heterozygous mutation c.2114 A>T, p.E705V, in the tail segment domain. Interestingly, the adjacent residue 706 is the site of the autosomal dominant LOF mutation L706S, 16 and the nearby mutant LOF Y701C associated with disseminated mycobacterial disease and ostemyelitis. 25 The mutation c.2114 A>T was not found in dbSNP 147, 1000 Genomes Project, or EXAC. 26 The patient's parents were not available for screening.
Functional assays
We performed direct testing of STAT1-mediated functions on the patient's frozen PBMCs. Stimulation of PBMCs with IFN-g and LPS plus IFN-g led to markedly enhanced expression of the interferon-inducible protein 10 (IP10) and CXCL9 genes (Fig 2, A) and to higher cytokine levels in the supernatants of cells from the patient (IP10: mean, 30,901 vs 10,393 pg/mL in control subjects; TNF-a, 47,332 vs 21,452 pg/mL; Fig 2, B) , respectively. T H 17 levels after stimulation with phorbol 12-myristate 13-acetate/ionomycin in the patient's T cells were decreased (0.4% positive cells) compared with those in control subjects (1.66% 6 0.2%; Fig 2, C) . Intracellular expression of TNF-a and IFN-g was preserved. Somewhat surprisingly, IFN-g-driven STAT1 phosphorylation in thawed PBMCs from the patient was essentially normal. However, after treatment with the kinase inhibitor staurosporine, the patient's pSTAT1 levels were 1.5-to 2-fold higher than normal (see Fig E1 in this article' s Online Repository at www.jacionline.org).
Because it was clear from clinical, sequence, and functional testing that this patient had severe GOF STAT1 disease, we pursued further molecular characterization of the identified mutation. We transfected E705V-STAT1 into STAT1-deficient U3C and U3A cells and used immunoblotting after IFN-g stimulation. In selected experiments we used staurosporine to block further phosphorylation and the phosphatase inhibitor pervanadate to block dephosphorylation. After treatment with staurosporine, STAT1 phosphorylation (pSTAT1) was increased in cells transfected with E705V-STAT1 compared with WT-STAT1 (Fig 3, A-C) . Similar results were observed when cells were transfected with the previously described sumoylationdeficient STAT1 mutant E705Q (Fig 3, C) . 15, 27 In addition, treatment of cells with pervanadate increased phosphorylation A, PBMCs from the patient and 2 healthy subjects were stimulated with IFN-g and assayed by using RT-PCR. Data represent the mean fold increase relative to unstimulated PBMCs (NS). B, Cytokine production (in picograms per milliliter) in response to LPS plus IFN-g. Assays were performed in triplicate. C, T H 17 response in PBMCs stimulated with phorbol 12-myristate 13-acetate/ionomycin. Dot plots are representative for each subjects. *P < .05 compared with healthy subjects.
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DNA-binding activity to the gamma-activating sequence motif after IFN-g activation was enhanced for E705V-STAT1 compared with WT-STAT1 (Fig 4, A) . Evaluation of gamma-activating sequence-luciferase reporter transcriptional activity was significantly increased for E705V-STAT1 compared with WT-STAT1 (Fig 4, B) but absent in cells transfected with the LOF mutants L706S or Y701C. Gene expression assayed in transfected cells showed that expression of the IFN-g-induced genes (IP10/ CXCL10, CIITA, and CXCL11) was higher with both E705V and E705Q mutants (Fig 4, C) . Moreover, cotransfection of E705V-STAT1 and WT-STAT1 led to enhanced transcriptional response and gene expression (Fig 4, B and C) , which is consistent with the dominant GOF activity of the mutant allele.
E705V mutation leads to defective sumoylation of STAT1
Equal amounts of protein were immunoprecipitated with anti-STAT1 antibody and immunoblotted with anti-STAT1 and anti-SUMO1 antibodies to determine whether E705V affected STAT1 sumoylation. SUMO-associated STAT1, identified as a slower migrating band (approximately 110-120 kDa), was detected in unstimulated WT transfected cells, confirming that STAT1 is sumoylated at steady state; the SUMO band was absent in E705V-STAT1 (Fig 5) , as well as in K703R (Fig 5, A and C) and E705Q (Fig 5, C and D) transfectants. Cells cotransfected with WT and E705V also had absent SUMO staining bands (Fig 5, B  and D) , which is consistent with the dominant nature of the STAT1 mutant construct. In contrast, the LOF STAT1 mutations at the adjacent residue L706S (Fig 5, A and C) and the nearby tyrosine-mutated Y701C (Fig 5, D) showed preserved SUMO-associated STAT1 in immunoprecipitates. SUMO1 was also detected in immunoprecipitated lysates obtained from U3C-transfected WT-STAT1 cells but was absent in the E705V-STAT1 samples (data not shown). Specificity of the assay was reinforced by the absence of STAT1 and SUMO bands after immunoprecipitation with the isotype antibody.
To further evaluate the importance of SUMOylation on STAT1 phosphorylation, we cotransfected COS-7 cells with WT-STAT1 and a construct expressing the deSUMOylating enzyme SENP1. After IFN-g stimulation, SENP1 cotransfected cells showed higher pSTAT1 levels than cells transfected with WT-STAT1 alone (see Fig E2 in this article' s Online Repository at www.jacionline.org).
Detection of nuclear paracrystals
The previous description of the assembly of nuclear paracrystals in SUMO-free STAT1-transfected cells after activation with IFN-g 15, 28 prompted us to examine whether the STAT1 mutant E705V led to assembly of similar paracrystals in activated cells. Confocal microscopy confirmed the ability of E705V-STAT1 to translocate to the nucleus after in vitro stimulation of cells with IFN-g and showed accumulation of SUMOfree E705V-STAT1 protein into punctate structures (Fig 6) . These structures were absent in IFN-g-activated WT-STAT1 cells.
STAT1 modeling
After initial minimization, the WT-STAT1 model generated by I-TASSER displays the phosphorylation site Tyr701 extending up to the solution phase and presumably more available for phosphorylation, similar to the 1BF5 crystal structure (Fig 7, A) . Leu706 is in a mostly hydrophobic pocket, as shown in the ribbon drawing of the C-terminal domain of STAT1 (Fig 7, B) . Although the MD simulation shows a fair amount of flexibility in the C-terminal loop, Leu706 tends to remain in the hydrophobic pocket and ''anchor'' the C-terminal end of the protein. This keeps Tyr701 pointing mostly into the solvent phase, although not necessarily in the same orientation as the crystal structure or the initial stages of the MD run. The L706S mutation leads to loss of a hydrophobic residue to anchor the C-terminal strand to the rest of the protein. During the MD simulation, it quickly opens up and rearranges so that Tyr701 now anchors the C-terminal region to the rest of the protein by forming hydrogen bonds with nearby acidic amino acids. Fig 7, B , shows the C-terminal domain from a representative snapshot in the simulation and depicts a hydrogen bond between Asp646 and Tyr701. In this state Tyr701 is mostly buried and presumably unavailable for phosphorylation (Fig 7, C) in which Tyr701 is colored red and is on the interior of the protein. Although sumoylation still occurs for this mutant, because the sumoylation consensus sequence is not affected, the lower accessibility of the phosphorylation site likely also decreases its phosphorylation and activity. In contrast, the E705V mutation makes the area around L706 even more hydrophobic, thereby helping to more tightly anchor the C-terminal strand to the rest of the protein. In particular, Val705 interacts with the a-helix residues Thr635 to Ala641 in addition to the parts of the hydrophobic pocket around Leu706 seen in the WT model. The C-terminal tail is much more rigid throughout the MD run, resulting in Tyr701 staying predominantly pointing into solution phase. This mutant also rather consistently displays the same ''up'' orientation seen in the 1BF5 crystal structure relative to the WT model (Fig 7, D) . This model suggests that the Tyr701 site is more available for phosphorylation, as shown in Fig 7, D, which shows the C-terminal domain from a representative snapshot from the MD simulation of E705V. The hydrophobic residues appear as line drawings surrounding V705 (in red stick representation). This figure also shows Tyr 701 as sticks pointing ''up,'' and the location of L706 (also in stick representation) is shown nearby in the extended hydrophobic pocket. The average solvent accessible surface area of Tyr701 throughout each of the 3 MD runs (WT, 23 A2; E705V, 29 A2; and L706S, 12 A2) illustrates the differences in the availability of the phosphorylation site, which occurs in the absence of SUMO. The dominant negative LOF mutant L706S has a significantly lower accessibility for Tyr701, which is predominantly buried during the MD run (Fig 7, C) . In contrast, the increase in pSTAT1 levels observed for E705V can correlate with more available Tyr701 for phosphorylation. 
DISCUSSION
This is the first pathologic identification of the critical role of sumoylation in STAT1 disease. The mutation at position 705, which lies at the C-terminal end of STAT1 in the consensus motif for sumoylation, disrupts SUMO conjugation to STAT1 and is associated with the occurrence of many of the typical STAT1 GOF clinical manifestations, including CMC, fatal squamous cell carcinoma, and endocrinopathies.
In addition, this is the first identified association of R equi, a gram-positive coccobacillus, in GOF STAT1 disease. R equi is a facultative intracellular opportunistic pathogen encountered in immunocompromised hosts, such as those with HIV/AIDS or transplantation. It is closely related to both Mycobacteria and Nocardia species, a fact that is likely relevant in its occurrence in patients with this disease. A recent report of immune reconstitution around R equi leading to cavitary pneumonia in an HIV-infected patient with Burkitt lymphoma 29 confirms a link of this organism to immune-mediated pathology.
Posttranslational modifications shape the response and fate of transcription factors after cell stimulation. SUMO proteins are (Fig 5, A and B) and Y701C (Fig 5, D) cells but absent in E705V (Fig 5, A-D) , K703R (Fig 5, A and B) , E705Q (Fig 5, B and D) , and E705V and WT-STAT1 (Fig 5, C and D) . In Fig 5, D , bands are absent after immunoprecipitation (IP) with the isotype antibody. Experiments were performed at least 3 times. WB, Western blotting. covalently attached to proteins, a phenomenon that is rapidly reversed by deSUMOylating enzymes or SENPs, which ultimately lead to detection of low levels of in vivo sumoylated proteins. [9] [10] [11] Proteomic studies point to approximately 3600 SUMO-targeted proteins, about 66% of which are thought to be nuclear. 30 Studies have shown that sumoylation of interferon regulatory factor (IRF) 3, IRF-7, and IRF-8 attenuates their function, 31, 32 whereas sumoylation of retinoic acid-inducible gene I and melanoma differentiation-associated protein positively regulates their function, leading to increased IFN-b expression. [33] [34] [35] Prior work identified STAT1 sumoylation as an important negative regulator of IFN-g signaling. [12] [13] [14] 27, 36 Although the Cterminal sumoylation sequence in STAT1, 702 KXTE 705 , is highly conserved across species, it is not conserved among other STAT molecules. 12 Disruption of the sumoylation motif with loss of SUMO conjugation to STAT1 has been described for the engineered mutants K703R, E705Q, and E705A. [12] [13] [14] E705V-STAT1 disrupts SUMO conjugation to STAT1 and results in enhanced transcriptional response to IFN-g, both in primary cells from the patient and in transfected cells.
Consistent with previous publications, 15, 37 we observed accumulation of punctate STAT1-containing paracrystals in the nuclei of E705V-transfected cells after IFN-g stimulation but not in the nuclei of those transfected with WT-STAT1. It is postulated that these crystals are less soluble but transcriptionally active. 15, 28 An additional study in mice expressing SUMO-free STAT1 37 also evidenced that lack of SUMO led to paracrystal formation of activated STAT1. Strikingly, the analogous sumoylation motif CKTE is naturally altered in STAT3 ( 706 LKTK 709 ), and after stimulation, WT-STAT3 can also form dimers that polymerize and assemble into punctate structures in the nuclei of cells. 15 Interestingly, there appear to be several levels of modulation exerted by sumoylation. First, Zimnik et al 38 have shown phosphorylation and sumoylation of STAT1 to be mutually exclusive. Second, SUMO is bulky and precludes phosphorylation of the nearby Tyr701 residue, and our modeling experiments indicate that in E705V the Tyr701 phosphorylation site is modestly more exposed than in WT. Tyr701 accessibility is probably not the primary mechanism for the increased activity of E705V-STAT1, but we believe it might be secondary to the elimination of the blocking effect of SUMO. Third, lack of SUMO, also seen in E705V, is associated with nuclear paracrystal formation. The observation of enhanced pSTAT1 in response to IFN-g after cotransfection with WT-STAT1 and SENP1 corroborate that disobstruction of Tyr701 by loss of SUMO is bound to enhanced phosphorylation and crystal formation, leading consequently to enhanced transcriptional response and play a major role in GOF. Fourth, Gr€ onholm et al 27 showed that E705Q-STAT1 disrupted sumoylation and exposed the site of interaction at the surface toward the DNA, leading to persistent DNA binding and enhanced activation compared with WT-STAT1. In addition, overexpression of the deSUMOylating (Fig 7, B) , and its surface representation is shown in red (Fig 7, C) . D, E705V makes the area around L706 more hydrophobic, allowing Tyr701 to point ''up.'' enzyme SENP1 reduced SUMO conjugation and led to enhanced DNA binding activity.
Our results reinforce the main effect of this mutant to be on the nuclear mechanisms of STAT1 activation. This is manifest by the multiple routes of clinical disease, mRNA transcription, protein expression, and transfection experiments. Despite the clear evidence of GOF STAT1 physiology, pSTAT1 levels in response to IFN-g in primary cells assayed in vitro were normal. These data suggest that pSTAT1 levels detected by using flow cytometry might be insensitive for GOF STAT1 detection in some cases.
The combination of availability, paracrystals, nuclear retention, enhanced DNA binding, and gene expression conspire to prolong STAT1 activation. SUMO conjugation is a critical component of cellular immune regulation after IFN-g activation and points to a novel regulatory mechanism for development of the GOF STAT1 phenotype. Moreover, the ability of SUMO to modulate STAT1 activation suggests new targets for therapeutic exploitation. 
